Company intelligence / Profile preview
Bruschettini
Genoa, Liguria, Italybruschettini.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Bruschettini sponsors a Phase 3 open-label extension study investigating the long-term safety, tolerability, and efficacy of tauroursodeoxycholic acid sodium for ALS, offering extended access and assessing longer-term outcomes in patients who have completed the TUDCA-ALS study[4].
- Therapeutic areas
- NeurologyGastroenterology
- Modalities
- Small moleculePharmaceutical productMedical deviceFood supplement
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
Beyond the preview
Go deeper on Bruschettini.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bruschettini.